Next Gen Pharma India Pvt. Ltd.
Quick facts
Phase 3 pipeline
- Lactobacillus brevis CD2 Lozenges · Immunology / Infectious Disease
Lactobacillus brevis CD2 is a probiotic lozenge that colonizes the oral and respiratory tract to modulate local and systemic immune responses.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: